See today's BioWorld
To read the full story, subscribe or sign in.

TolerRx Closes $35M Series C, Collaborates With Genentech

Jan. 6, 2003
By Brady Huggett
TolerRx Inc. is off and running, closing a $35 million Series C round and signing monoclonal antibody heavyweight Genentech Inc. to a co-development deal for TolerRx's lead product, TRX1. (BioWorld Today)
BioWorld